Evaluating Twist Bioscience: Insights From 5 Financial Analysts
Portfolio Pulse from Benzinga Insights
Over the past three months, five analysts have evaluated Twist Bioscience (NASDAQ:TWST), with a mix of bullish and somewhat bullish ratings. The average 12-month price target has increased by 20.65% to $55.8. Analysts from firms like Baird, Goldman Sachs, Barclays, TD Cowen, and Guggenheim have raised their price targets and ratings for TWST.
August 05, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have shown increased confidence in Twist Bioscience, raising the average 12-month price target by 20.65% to $55.8. Major firms like Baird, Goldman Sachs, Barclays, TD Cowen, and Guggenheim have raised their ratings and price targets.
The increase in the average 12-month price target and the bullish ratings from major analyst firms indicate a positive short-term outlook for TWST. This is likely to boost investor confidence and drive the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100